SEOUL (SOUTH KOREA) – Celltrion Inc said on Thursday said it has received regulatory approval from British authorities for a phase I clinical trial of its experimental COVID-19 antibody drug.
The pharmaceutical firm will rope in participants for a clinical study in the UK following approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), it said.
On July 17, South Korean regulators had given the nod for an early stage clinical trial for the drug, making it the country’s first such antibody drug to be tested on humans.
(Photos syndicated via Reuters)
This story has been edited by BH staff and is published from a syndicated field
